Neurostimulation and implantable drug delivery reach critical mass and promise continued rapid growth
This article was originally published in Clinica
Executive Summary
The combined neurostimulation and implantable drug delivery businesses now represent a $540 million worldwide market, growing at 25% to 30% a year. They have the potential to grow at this rate for the next five years, but they would still barely penetrate what is conservatively calculated to be a potential $3 billion to $5 billion market.